Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Clinicopath Conf., Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 348:735-743, Case 6-2003, 2003
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
CIDP:Clinical Features & Responses to Trtm in 67 Consecutive Pts with/without a Monoclonal Gammopathy
Neurol 48:321-328, Gorson,K.G.,et al, 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Children
Muscle & Nerve 20:1569-1575997., Simmons,Z.,et al, 1997
Idiopathic Dysautonomia Treated with Intravenous Gammaglobulin
Lancet 347:28-29, Heafield,M.T.E.,et al, 1996
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Chronic Inflammatory Demyelinating Polyradiculoneuropathy:Unusual Clinical Features and Therapeutic Responses
Neurol 46:1206-1212, Midroni,G.&Dyck,P.J., 1996
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
CIDP of Childhood:Treatment with High-Dose Intravenous Immunoglobulin
Neurol 41:828-830, Vedanarayanan,V.V.,et al, 1991
Clinical Uses of Intravenous Immunoglobulins
Ann Int Med 112:278-292, Berkman,S.A.,et al, 1990
An 8-Year-Old with Acute Onset Ataxia
Neurol 99:305-310, McLaren, J.R.,et al, 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Guillain-Barre Syndrome Associated with JEV Infection
NEJM 383:1188-1190, Wang, G.,et al, 2020
Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018
Acute Onset of Diplopia in Pregnancy
Neurol 91:e180-e184, Munro, Z. & Fernandez, D., 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Paraparetic Guillain-Barre Syndrome
Neurol 82:1984-1989, Van Den Berg, B.,et al, 2014
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Clinical Reasoning: A 34-year-old man with recurrent limb weakness
Neurol 77:e68-e72, Karam, C.,et al, 2011
Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Classifications and Treatment Responses in Chronic Immune-Mediated Demyelinating Polyneuropathy
Neurol 68:1622-1629, Tackenberg,B.,et al, 2007
Clinical and Electrophysiologic Correlates of IVIg Responsiveness in CIDP
Neurol 64:1471-1475, Iijima,M.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Randomized Controlled Trial of IVIg in Untreated Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Neurol 56:445-449, Mendell,J.R.,et al, 2001
Randomized Controlled Trial of Intravenous Immunoglobulin Versus Oral Prednisolone in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Ann Neurol 50:195-201, Hughes,R.,et al, 2001
Outcome in Severe Pediatric Guillain-Barre Syndrome after Immunotherapy or Supportive Care
Neurol 52:1494-1497, Graf,W.D.,et al, 1999
Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999
The Use of Self Infused IVIG Home Therapy in Trtm of Acquired Chronic Demyel Neuropathies
JNNP 63:106-109, Sewell,W.A.C.,et al, 1997
Reversible Encephalopathy with Cerebral Vasospasm in a Guillain-Barre Syndrome Patient Treated with Intravenous Immunoglobulin
Neurol 46:250-251, Voltz,R.,et al, 1996
Liver Function Disturbances in Guillain-Barre Syndrome:A Prospective Longitudinal Study in 100 Patients
Neurol 46:96-100, Oomes,P.G.,et al, 1996
Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996
Campylobacter Jejuni Infection and Anti-GM1 Antibodies in Guillain-Barre Syndrome
Ann Neurol 40:181-187, Jacobs,B.C.,et al, 1996
Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996
Lyme Radiculoneuritis Treated with Intravenous Immunoglobin
Neurol 46:1174-1175, Crisp,D.&Ashby,P., 1996
Acute Paresis of Extraocular Muscles Associated with IgG Anti-GQ Antibody
Ann Neurol 39:668-672, Yuki,N., 1996
The Restoration of IVIg Efficacy by Plasma Exchange in CIDP
Neurol 45:1628-1629, Berger,A.R.,et al, 1995
Successful Treatment of Neuropathies in Patients with Diabetes Mellitus
Arch Neurol 52:1053-1061, Krendel,D.A.,et al, 1995
Treatment of Guillain-Barre Syndrome with High-Dose Immune Globulins-Combined with Methylprednisolone:Dutch Guillain-Barre Study Group
Ann Neurol 35:749-752, , 1994
A Plasma Exchange Versus Immune Globulin Infusion Trial in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Ann Neurol 36:838-845, Dyck,P.J.,et al, 1994
Intravenous Immunoglobulin Treatment in PTs with Chronic Inflammatory Demyelinating Polyneuropathy
JNNP 56:36-39, Vermeulen,M.,et al, 1993